Mandated step therapy for dupilumab delays the inevitable

Brian Florenzoa University of Virginia School of Medicine, Charlottesville, VA, USA

Catherine E. Lyonsa University of Virginia School of Medicine, Charlottesville, VA, USACorrespondence[email protected]

Aaron D. Smitha University of Virginia School of Medicine, Charlottesville, VA, USA

Courtney Remingtonb Department of Dermatology, University of Virginia Medical Center, Charlottesville, VA, USA

R. Hal. Flowersb Department of Dermatology, University of Virginia Medical Center, Charlottesville, VA, USA

Bridget Bryerb Department of Dermatology, University of Virginia Medical Center, Charlottesville, VA, USA

"Mandated step therapy for dupilumab delays the inevitable." Journal of Dermatological Treatment, 35(1), pp.

Disclosure statement

Dr. Flowers serves as a principal investigator for Abbvie, Acelyrin, Regeneron/Sanofi and Sun Pharmaceuticals. He has served on advisory boards for Argenx, Bristol-Myers Squibb and Janssen.

Mandated step therapy for dupilumab delays the inevitable

Information for

Open access

Opportunities

Help and information

Mandated step therapy for dupilumab delays the inevitable

Disclosure statement

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature